Announced
Completed
Financials
Sources
Tags
Majority
Completed
Private
Acquisition
Single Bidder
Private Equity
Friendly
Biotechnology
biotechnology company
United States
Domestic
Synopsis
Investors consortium completed the $700m investment in Sana Biotechnology, a developer of engineered cells intended to be used as medicine for patients. "Sana is dedicated to modulating genes in cells as well as replacing damaged cells in the body. The commitment from this group of long-term investors enables us to concentrate on making discoveries that overcome the most important challenges to making gene and cell therapies that improve the lives of a broad swath of patients. I am proud of our progress to date in turning our technologies into potential therapies for serious diseases such as cancer, central nervous system diseases, heart disease and various genetic disorders," Steve Harr, Sana President and CEO
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.